Article Details
Retrieved on: 2021-01-11 16:42:55
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
“We see the science is reinforced today with the news from another very important company [Lilly]. ... In response to investor questions, which focused heavily on aducanumab, Al Sandrock, head of Biogen's R&D, said he did see a ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here